Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

CareDx is well-positioned for growth in the transplant market, with a strong focus on precision medicine and a diversified portfolio of testing services. While there may be potential challenges in commercializing new products, the company's solid financial performance and strategic investments bode well for long-term success. With a promising new product on the horizon and a commitment to reaching their financial targets, CareDx appears to be a strong investment opportunity in the healthcare sector.

Bears say

CareDx is a precision medicine company focused on the discovery, development, and commercialization of high-value healthcare solutions for transplant patients. The company's recent earnings call and investor meeting schedule forecasted strong financial targets for 2026 and 2027, including a 15% revenue CAGR, >70% gross margin target, and 20% Adj. EBITDA margin target. However, we have concerns about its reliance on acquisitions for growth, potential regulatory challenges, and competition from Natera in the transplant market.

CareDx (CDNA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 5 analysts, CareDx (CDNA) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.